Pharma manufacturing news in brief
pharmafile | August 19, 2011 | News story | Manufacturing and Production |Â Â pharma manufacturing newsÂ
Lonza launches a stripped down material supply service for biologics developers, plus facility news from United Therapeutics, Dr Reddy’s and West Pharma and an IPO for Indian contract manufacturer Brooks Laboratories.
Swiss contract manufacturer Lonza has launched a new material supply service – called Light Path – for companies developing early-stage biologic drugs in mammalian and microbial systems. The service is a “collection of basic supply services that give customers a simpler, faster and more cost-effective way to obtain biological material,” according to Janet White, Lonza’s head of development services.
United Therapeutics is expanding its Research Triangle Park facilities as it shifts packaging, labelling and distribution of its products in-house, according to a report in the Durham Herald Sun. The company started building an 180,000 sq.ft. extension to its existing 200,000 sq.ft. unit in May and expects to complete construction in the middle of next year. The cost of the new build is expected to be around $74 million.
Staff at a Dr Reddy’s Laboratories facility in Srikakulum, India, have gone on strike in order to demand higher salaries, according to local news reports. Around 600 workers at the active pharmaceutical ingredient (API) plant have taken part in the action, which started on 12 August. The company has been negotiating with the workforce at the plant for some time, but talks broke down last week.
Indian contract research and manufacturing services (CRAMS) company Brooks Laboratories has embarked on an initial public offering which closed on 18 August. The company says it intends to use the funds raised to set up a manufacturing unit in Gujarat and for working capital. The company already operates a 75,000 sq.ft. facility at Baddi in Himachal Pradesh, which specialises in oral, injectable and liquid dosage forms.
West Pharmaceuticals is expanding and upgrading an R&D facility in Florida, USA, that will focus on developing new elastomer formulations and process technologies for products in the company’s medical component business. The expansion, which will include new mixing, compounding and moulding equipment, is due to complete in October.
Phil Taylor
Related Content
Pharma manufacturing news in brief
Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates …
Bayer planning joint venture to make drugs in Russia
Germany’s Bayer AG has joined a number of its peers in the pharmaceutical industry with …
Pharma manufacturing news in brief
FDA sets aside $35m for manufacturing research, Anteco, Apicore and Vetter provide facility updates and …
